Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B

Abstract

Background: HBV infection is a serious global heath problem. It is crucial to monitor this disease more closely with a non-invasive marker in clinical trials. We aimed to evaluate the predictive value of serum hyaluronate for the presence of extensive liver fibrosis and inflammation.

Dimethylnitrosamine (DMN)-induced fibrotic rats: effect of Vernonia amygdalina on extracellular matrix and Hepatic/lysosomal integrity

“…Comparing serum hyaluronic acid levels with histological fibrosis in children with biliary atresia, Kobyashi et al (1999) and Hasegawa et al (2000) showed that significant fibrosis correlated with increased hyaluronic acid levels. Montazeri et al (2005) reported a relationship between serum hyaluronate and the severity of inflammation and fibrosis in patients with non-HBsAg hepatitis B. Furthermore; the study of Hartley et al (2006) confirmed these findings in a sample of unselected children undergoing liver biopsy.…”

Noninvasive assessment of liver fibrosis with combined serum aminotransferase/platelet ratio index and hyaluronic acid in patients with chronic hepatitis B

“…Kuroiwa et al [6] showed that the AUC value of HA for any fibrosis and cirrhosis is higher than 0.5. Montazeri et al [14] demonstrated that serum HA is a preferred marker of severe fibrogenesis and inflammation in CHB patients. HA at a cutoff point of 126.4 µg/L can detect severe fibrosis with a sensitivity of 90.9% and a specificity of 98.1%.…”

Study of Some Serum Biochemical Markers of Liver Fibrosis in Patients with Chronic HCV

“…We found that serum level of hyaluronic acid was significantly higher in group 2 than in group 1 with a cut-off level ≥ 48 ng/mL, P-value=0.0001 and R=0.51 with a NPV ≥ 96% and specifity 48%. A similar study was done by Sakugawa et al and Murawaki et al [25] who had defined a cutoff level of ≥50 ng/mL for detection of severe fibrosis; in another study Montazeri et al used a cut off level of 126.4 ng/mL [26]. HA has been studied in CHC, NAFLD, alcoholic liver disease (ALD), and CHB, but it has been more extensively studied in the former two diseases.…”